April 04,2019
Grassley Praises House Action Advancing Bills to Reduce Prescription Drug Costs
CREATES Act Unanimously Clears Energy & Commerce Committee
WASHINGTON
– The House Energy and Commerce Committee approved by a vote of 51-0 its
version of the CREATES Act, which is cosponsored
in the Senate by Finance Committee Chairman Chuck Grassley. The CREATES Act addresses abuses by
brand-name drug companies that keep lower-cost generic alternatives from being
developed or reaching the market. The legislation is estimated to saves
taxpayers roughly $3.9 billion over 10 years. The House committee also advanced
by voice vote a bill to end anti-competitive pay-for-delay agreements between
brand-name drugmakers and generic manufacturers that keep lower-cost
alternative drugs off the market. Grassley is the lead Republican cosponsor of separate
bipartisan legislation in the Senate to address pay-for-delay.
“Few
proposals get unanimous support these days. Yesterday’s broad, bipartisan action
by the House Energy and Commerce Committee to advance the CREATES Act is a major win for consumers. I look forward to
advancing this bill because it will cut down on abuses in the system that keep
prices high for patients. I’m also pleased that the committee advanced a bill
to address pay-for-delay schemes. Although that bill is not identical to the
bill I’ve sponsored in the Senate, the bill’s movement shows that the committee
is serious about addressing the pay-for-delay problem. I’ll continue to push
for legislation to address abuse and improve competition in the prescription
drug market. I’ll also continue working to bring transparency to the business
model and supply chain that is causing unnecessarily high prices for American
patients and taxpayers,” Grassley said.
Grassley
held two hearings this year on drug
pricing in America, including one with seven
leading drug manufacturers, and has scheduled a hearing with five pharmacy
benefit managers (PBMs) for next week. He is also leading
a bipartisan investigation with Senate Finance Committee Ranking
Member Ron Wyden into the recent spike in the price of insulin.
-30-
Next Article Previous Article